Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence.
The durability of Janus kinase (JAK) inhibitors in routine clinical practice is still debated. This study aimed to compare the drug retention rates of selective JAK1 inhibitors (upadacitinib, filgotinib) with pan-JAK inhibitors (tofacitinib, baricitinib) in patients with rheumat…